Dolutegravir (4, reassessment) (Tivicay®) – HIV infection, age 6 to < 18 years

Characteristics

Start date 01.04.2022
Resolution 15.09.2022
INN Dolutegravir
Brand name Tivicay®
Pharm. company ViiV Healthcare GmbH
Therapeutic area Infectious diseases
Reason for procedure Resolution w/o assessement – Non-amendment of original resolution
Original resolution: Dolutegravir (2) (21.09.2017)

9. Associated procedures



<< List of all resolutions